All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
LONDON – Neurodegenerative disease start-up Denali Therapeutics Inc. announced a slew of deals and collaborations, with a potential $1 billion agreement with bispecific antibody specialist F-star Ltd. heading the list.